SRPT
Sarepta Therapeutics, Inc.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #814
- Final score
- 32.55
- Years on list
- 6
↗ Climbed 147 since 2020
Compare · Up to four Russell 1000 companies
Put them side by side
Select two, three, or four Russell 1000 companies to compare their overall rank, year-by-year trajectory, and scores down to the category level.
- SRPT· Sarepta Therapeutics, Inc.
- EXEL· Exelixis, Inc.
- NBIX· Neurocrine Biosciences, Inc.
Figure 01 · Side-by-side summary
The headline numbers
EXEL
Exelixis, Inc.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #811
- Final score
- 32.79
- Years on list
- 6
↘ Down 199 since 2020
NBIX
Neurocrine Biosciences, Inc.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2025
- #827
- Final score
- 31.40
- Years on list
- 6
↗ Climbed 2 since 2020
Figure 02 · Rank trajectory
Where each line is going
Lower is better. The y-axis is inverted so a rising line means an improving rank. Missing years mean the company didn't make the top 100 that year.
Figure 03 · Pillar profile · 2025
Where each one wins
Latest-year ESG pillar scores, 0–100. The shaded bar shows relative strength across the selected companies for each pillar.
| Pillar | SRPT | EXEL | NBIX |
|---|---|---|---|
| Climate Change | 44.0 | 24.5 | 30.8 |
| Employee Relations | 33.5 | 44.8 | 36.5 |
| Environment | 30.9 | 46.2 | 31.9 |
| Stakeholders & Society | 23.6 | 28.6 | 22.4 |
| Human Rights | 5.7 | 6.3 | 16.4 |
| Governance | 41.5 | 28.1 | 44.2 |
| Performance Rating | 54.9 | 49.1 | 48.1 |